A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection
To evaluate the efficacy and safety of TQB6411 for injection in trial participant with advanced lung cancer
Trial Details
- NCT ID
- NCT07367529
- Phase
- PHASE1 / PHASE2
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Status
- RECRUITING
- Cancer Type
- Lung Cancer
- Interventions
- Locations (sample)
- Beijing, Beijing Municipality, China|39.9075,116.39723
- Beijing, Beijing Municipality, China|39.9075,116.39723
- Chongqing, Chongqing Municipality, China|29.56026,106.55771
- Guangzhou, Guangdong, China|23.11667,113.25
- Guanzhou, Guangdong, China|23.06828,113.37117
Key Eligibility Criteria
- Participants voluntarily participate in this study, sign the informed consent form, and demonstrate good compliance;
- Age between 18 and 75 years (calculated based on the date of signing the informed consent form);
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1;
- Expected survival greater than 12 weeks;
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Lung Cancer Trials on Trialify →